Phaseline

Companies › Viatris

Viatris: clinical trials, targets and expected readouts

3 active drug programs in 18 registered trials: 6 Phase 4, 5 Phase 1, 4 Phase 2, 3 Phase 3; Ophthalmology, Neurology, Infectious disease, Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Gabapentin
Voltage-gated calcium channel modulator
Ion channels, CACNB4, CACNB2, CACNB1, CACNB3Phase 4Healthy; Tonsillitis; Dental Pain and Sensation Disorder; Pain, Postoperative …Jan 2027
Fluticasone Propionate
Glucocorticoid receptor agonist
NR3C1Phase 4Allergic Rhinitis Due to Allergens–
MR-146
Gene therapy for neurotrophic keratopathy
–Phase 1Neurotrophic KeratopathyNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03625011GabapentinPhase 4TonsillitisRespiratoryDec 2019
NCT03825809GabapentinPhase 2Narcotic UseOtherJan 2020
NCT06752486GabapentinPhase 1Pain After Photorefractive KeratectomyOphthalmologyMay 2025
NCT05921604GabapentinPhase 3Post Operative PainOtherAug 2025
NCT07597473Fluticasone PropionatePhase 4Allergic Rhinitis Due to AllergensImmunologySep 2026
NCT04860141GabapentinPhase 4Dental Pain and Sensation DisorderOtherDec 2026
NCT05664464GabapentinPhase 1GlioblastomaOncologyDec 2026
NCT05156060GabapentinPhase 1Head and Neck CancerOncologyDec 2026
NCT06379425GabapentinPhase 4Pain, PostoperativeNeurologyJan 2027
NCT07813026GabapentinPhase 4HealthyOtherJan 2027
NCT07916116GabapentinPhase 2Postdural Puncture Headache (PDPH)NeurologyMar 2027
NCT05443555GabapentinPhase 2HIVInfectious diseaseJun 2027
NCT07923045MR-146Phase 1Neurotrophic KeratopathyOphthalmologyNov 2027
NCT07308717GabapentinPhase 4Breast CancerOncologyDec 2027
NCT03498261GabapentinPhase 1Pain, PostoperativePsychiatryDec 2027
NCT04724252GabapentinPhase 2Pain, PostoperativeOtherDec 2027
NCT05827159GabapentinPhase 3Alcohol Use DisorderPsychiatryAug 2028
NCT06992427GabapentinPhase 3Head and Neck Squamous Cell CarcinomaOncologyAug 2029

From the company's SEC filings

Cash of $1.8bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

Ion channels (1) CACNB4 (1) CACNB2 (1) CACNB1 (1) CACNB3 (1) NR3C1 (1)

Companies with the same targets

Brainfarma Industria Química e Farmacêutica S/A Corcept Therapeutics Xenon Pharmaceuticals Pacira Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.